MEK inhibition causes Bim stabilization and sensitivity to Bcl2 family member inhibitors in RAS-MAPK mutated neuroblastoma
Eleveld, T. F.; Vernooij, L.; Schild, L.; Koopmans, B.; Alles, L. K.; Ebus, M. E.; van Sluis, P. G.; Caron, H. N.; Koster, J.; Versteeg, R.; Dolman, E. M.; Molenaar, J. J.
Show abstract
Mutations affecting the RAS-MAPK pathway occur frequently in relapsed neuroblastoma tumors and are associated with response to MEK inhibition in vitro. However, these inhibitors alone do not lead to tumor regression in vivo, indicating the need for combination therapy. Through high throughput combination screening we identify Trametinib and inhibitors of the BCL2 family (Navitoclax and Venetoclax) as a promising combination in neuroblastoma cells with RAS-MAPK mutations. In these lines, inhibiting the RAS-MAPK pathway leads to Bim stabilization and increased sensitivity to compounds inhibiting Bim binding to Bcl2 family members. Combining Trametinib with BCL2 inhibitors causes increased growth inhibition compared to Trametinib only in NRAS mutant SKNAS xenografts, while BCL2 inihibitors alone do not affect growth of these tumors. These results show that MEK inhibitors and specific Bcl2 family member inhibitors are a potent combination for RAS-MAPK mutated neuroblastoma tumors.
Matching journals
The top 15 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- PKIS Deep Dive Yields a Chemical Starting Point for Dark Kinases and a Cell Active BRSK2 Inhibitor 93%
- Collateral Responses to Classical Cytotoxic Chemotherapies are Heterogeneous and Sensitivities are Sparse 93%
- In silico drug sensitivity predicts subgroup-specific therapeutics in medulloblastoma patients 93%
Similar papers in this journal
- An unbiased high-throughput drug screen reveals a potential therapeutic vulnerability in the most lethal molecular subtype of pancreatic cancer 93%
- Inhibition of autophagy as a novel therapy for the treatment of neurofibromatosis type 1 tumors 92%
- PARP inhibition and pharmacological ascorbate demonstrate synergy in castration-resistant prostate cancer 91%
Similar papers in this journal
- Testing of the survivin suppressant YM155 in a large panel of drug-resistant neuroblastoma cell lines 94%
- Drug-adapted cancer cell lines reveal drug-induced heterogeneity and enable the identification of biomarker candidates for the acquired resistance setting 93%
- Differences in durability of PARP inhibition by clinically approved PARP inhibitors: implications for combinations and scheduling 92%
Similar papers in this journal
- Improving the power of drug toxicity measurements by quantitative nuclei imaging 93%
- The CDK12 inhibitor SR-4835 functions as a molecular glue that promotes cyclin K degradation in melanoma 93%
- Inhibiting BCKDK in triple-negative breast cancer suppress protein translation, impair mitochondrial function, and potentiate doxorubicin cytotoxicity 92%
Similar papers in this journal
- Pharmacogenomic synthetic lethal screens reveal hidden vulnerabilities and new therapeutic approaches for treatment of NF1-associated tumors 94%
- ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms 92%
- Anticancer efficacy of KRASG12C inhibitors is potentiated by PAK4 inhibitor KPT9274 in preclinical models of KRASG12C mutant pancreatic and lung cancers 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.